• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ALRN

    Aileron Therapeutics Inc.

    Subscribe to $ALRN
    $ALRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. Aileron Therapeutics, Inc. has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

    IPO Year: 2017

    Exchange: NASDAQ

    Website: aileronrx.com

    Peers

    $CLDX
    $JNCE
    $ONTX
    $MCRB
    $VKTX

    Recent Analyst Ratings for Aileron Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    Aileron Therapeutics Inc. SEC Filings

    See more
    • SEC Form 8-K filed by Aileron Therapeutics Inc.

      8-K - Rein Therapeutics, Inc. (0001420565) (Filer)

      1/10/25 4:06:34 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Aileron Therapeutics Inc.

      8-K - Aileron Therapeutics, Inc. (0001420565) (Filer)

      11/14/24 4:08:01 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Aileron Therapeutics Inc.

      10-Q - Aileron Therapeutics, Inc. (0001420565) (Filer)

      11/14/24 4:03:30 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Aileron Therapeutics Inc.

      SCHEDULE 13G/A - Aileron Therapeutics, Inc. (0001420565) (Subject)

      11/5/24 5:17:59 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Aileron Therapeutics Inc.

      8-K - Aileron Therapeutics, Inc. (0001420565) (Filer)

      8/21/24 4:17:00 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aileron Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Aileron Therapeutics, Inc. (0001420565) (Filer)

      8/14/24 5:23:53 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Aileron Therapeutics Inc.

      10-Q - Aileron Therapeutics, Inc. (0001420565) (Filer)

      8/14/24 5:12:55 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Aileron Therapeutics Inc.

      8-K - Aileron Therapeutics, Inc. (0001420565) (Filer)

      7/26/24 4:36:00 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Aileron Therapeutics Inc.

      424B5 - Aileron Therapeutics, Inc. (0001420565) (Filer)

      7/26/24 4:33:11 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Aileron Therapeutics Inc.

      424B5 - Aileron Therapeutics, Inc. (0001420565) (Filer)

      7/26/24 4:29:40 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Aileron Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Aileron Therapeutics to be Included in the Russell Microcap® Index

      AUSTIN, Texas, July 1, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S.

      7/1/24 8:00:00 AM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

      Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of 2024 Cash runway expected to fund operations and key milestones into the fourth quarter of 2024 AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. ("Aileron", the "Company", "we", "our" or "us") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the fourth quarter and full year ended Decemb

      4/15/24 5:20:25 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aileron Therapeutics Announces CEO Transition

      Current President and Chief Operating Officer, Brian Windsor, Ph.D., appointed Chief Executive Officer Dr. Windsor to lead Aileron into a new era focused on advancing a pipeline of first-in-class medicines for orphan pulmonary and fibrosis diseases WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that current President and Chief Operating Officer, Brian Windsor, Ph.D., has been appointed President and Chief Executive Officer (CEO) and will join th

      3/12/24 8:00:00 AM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

      Company continues to advance ALRN-6924 as a selective chemoprotective agent for all patients with p53-mutated cancer, with immediate focus on breast cancer clinical trialExtended cash runway expected to support operations through end of 1Q 2024Presented new data at the Society for Investigational Dermatology 2022 Annual Meeting suggesting ALRN-6924's potential to protect against chemotherapy-induced alopeciaReported new data from healthy volunteer study demonstrating ALRN-6924-induced cell cycle arrest in hair follicles and suggesting that higher levels of ALRN-6924 may generally prolong cell cycle arrestStrengthened management team with appointment of Susan L. Drexler as interim Chief Finan

      8/15/22 4:15:00 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical Operations

      Mr. Zergebel brings over 20 years of industry experience, primarily focused in oncology, and broad expertise to help Aileron ensure operational excellence Aileron is advancing ALRN-6924 with the goal of delivering a chemoprotective agent for patients with p53-mutated cancerClinical trial of ALRN-6924 in p53-mutated non-small cell lung cancer ongoing with interim data on track for June 2022Clinical trial of ALRN-6924 in p53-mutated neoadjuvant breast cancer anticipated to initiate enrollment in 2Q 2022 BOSTON, April 21, 2022 (GLOBE NEWSWIRE) --  Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to sav

      4/21/22 8:00:00 AM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Aileron Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Aileron Therapeutics Inc. (Amendment)

      SC 13D/A - Aileron Therapeutics, Inc. (0001420565) (Subject)

      4/16/24 5:16:57 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aileron Therapeutics Inc.

      SC 13G - AILERON THERAPEUTICS INC (0001420565) (Subject)

      3/5/24 7:14:50 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aileron Therapeutics Inc. (Amendment)

      SC 13G/A - AILERON THERAPEUTICS INC (0001420565) (Subject)

      2/14/24 10:28:12 AM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aileron Therapeutics Inc. (Amendment)

      SC 13G/A - AILERON THERAPEUTICS INC (0001420565) (Subject)

      2/5/24 1:20:21 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aileron Therapeutics Inc.

      SC 13G - AILERON THERAPEUTICS INC (0001420565) (Subject)

      11/13/23 5:08:06 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Aileron Therapeutics Inc. (Amendment)

      SC 13D/A - AILERON THERAPEUTICS INC (0001420565) (Subject)

      11/3/23 4:30:24 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aileron Therapeutics Inc. (Amendment)

      SC 13G/A - AILERON THERAPEUTICS INC (0001420565) (Subject)

      2/14/23 11:42:40 AM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aileron Therapeutics Inc. (Amendment)

      SC 13G/A - AILERON THERAPEUTICS INC (0001420565) (Subject)

      2/14/23 7:54:11 AM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aileron Therapeutics Inc. (Amendment)

      SC 13G/A - AILERON THERAPEUTICS INC (0001420565) (Subject)

      2/14/22 9:02:36 AM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - AILERON THERAPEUTICS INC (0001420565) (Subject)

      2/10/21 9:53:41 AM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Aileron Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Windsor James Brian bought $898 worth of shares (400 units at $2.24) (SEC Form 4)

      4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)

      12/9/24 4:09:30 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Aivado Manuel

      4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)

      12/6/24 4:41:02 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ambros Reinhard J.

      4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)

      12/6/24 4:38:23 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Fairey William

      4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)

      12/6/24 4:35:04 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Von Rickenbach Josef H

      4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)

      12/6/24 4:34:58 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Musso Alan A

      4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)

      12/6/24 4:32:48 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Windsor James Brian

      4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)

      12/4/24 4:05:08 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Aivado Manuel

      4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)

      8/22/24 4:09:02 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Von Rickenbach Josef H

      4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)

      8/22/24 4:07:24 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Fairey William

      4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)

      8/22/24 4:06:55 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Aileron Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

      High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and decreased the expression of a biomarker indicative of epithelial health and lung function decline, suggesting potential therapeutic effect Positive trend observed in seven out of eight IPF biomarkers in Cohort 2, with four biomarkers statistically significant in the combined Cohort 1 and Cohort 2 data set, and dose dependent movement of five biomarkers compared to low dose LTI-03 indicative of active LTI-03 pharmacodynamics High-dose LTI-03 was well-tolerated, with no safety signals observed Planning is underway for a Phase 2

      11/13/24 7:00:00 AM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

      Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker indicative of epithelial health, suggesting potential therapeutic effect Positive trend was observed in seven of eight IPF biomarkers evaluated Low-dose LTI-03 was well-tolerated, with no safety signal observed Data from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) is expected in the third quarter of 2024 Company to host conference call on Wednesday, May 1st at 9:00 am ET WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ

      5/1/24 8:30:23 AM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

      Patients on ALRN-6924 were able to stay on treatment longer, completing more of the first 4 cycles of carboplatin/pemetrexed (93% of cycles on ALRN-6924 versus 78% on placebo); this imbalance between treatment arms may have introduced a bias against ALRN-6924 on the composite primary endpoint  Evaluating cycles 1-6, the imbalance increases further (79% of cycles on ALRN-6924 versus 57% on placebo) Interim finding on the trial's composite primary endpoint, which was the proportion of treatment cycles free of Grade ≥3 neutropenia, anemia, thrombocytopenia, blood transfusions, use of growth factors, dose reductions/delays in the first 4 cycles, demonstrated 56% of cycles on ALRN-6924 ve

      6/29/22 6:30:55 AM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Aileron Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aileron Therapeutics Announces Rebranding to Rein Therapeutics

      Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets Company shares to begin trading on Nasdaq under the trading symbol "RNTX" effective January 13, 2025 AUSTIN, Texas, Jan. 10, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), formerly known as Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has changed its name to Rein Therapeutics, Inc. The new

      1/10/25 11:30:00 AM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

      Announced promising safety and positive biomarker data from Cohort 2 (5mg BID) of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients demonstrating dose dependent effects in five biomarkers evaluated compared to low dose LTI-03 Data from Cohort 2 of the Phase 1b clinical trial confirms results from Cohort 1, with four biomarkers achieving statistical significance in the combined Cohort 1 and Cohort 2 data set Planning is underway for a Phase 2 clinical trial AUSTIN, Texas, Nov. 14, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significan

      11/14/24 4:15:00 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

      High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and decreased the expression of a biomarker indicative of epithelial health and lung function decline, suggesting potential therapeutic effect Positive trend observed in seven out of eight IPF biomarkers in Cohort 2, with four biomarkers statistically significant in the combined Cohort 1 and Cohort 2 data set, and dose dependent movement of five biomarkers compared to low dose LTI-03 indicative of active LTI-03 pharmacodynamics High-dose LTI-03 was well-tolerated, with no safety signals observed Planning is underway for a Phase 2

      11/13/24 7:00:00 AM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis

      First scientific presentation of previously announced data from Cohort 1 of the ongoing Phase 1b clinical trial evaluating low-dose LTI-03 (2.5 mg BID) in IPF, affirms positive trends in seven of the eight biomarkers evaluated, suggesting potential therapeutic effect Recently completed enrollment of Cohort 2 evaluating high-dose LTI-03 (5 mg BID) in mid-September; topline data expected in the near-term AUSTIN, Texas, Oct. 12, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the pr

      10/12/24 9:00:00 AM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

      Cohort 2 will evaluate high-dose LTI-03 (5 mg BID) Previously announced Cohort 1 data demonstrated positive trends in seven of the eight biomarkers evaluated, suggesting a potential therapeutic effect AUSTIN, Texas, Sept. 23, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the completion of enrollment in Cohort 2 of the ongoing Phase 1b clinical trial of LTI-03 in IPF patients.

      9/23/24 7:30:00 AM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aileron Therapeutics to Present at the 8th Annual IPF Summit

      AUSTIN, Texas, Aug. 19, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer of Aileron, will present at the 8th Annual IPF Summit taking place August 20-22, 2024 in Boston, MA. Details of the presentation are as follows: Presentation Title: Biomarker Strategies in the Clinical Development of LTI-03 in IPFS

      8/19/24 4:05:00 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

      Announced positive data from Cohort 1 of the ongoing Phase 1b clinical trial of LTI-03 evaluating low dose LTI-03 (2.5 mg BID) in idiopathic pulmonary fibrosis ("IPF") patients, with positive trends observed in seven of the eight biomarkers evaluated Topline results from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) expected in the third quarter of 2024 AUSTIN, Texas, Aug. 14, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ:ALRN), a biopharmaceutical company advancing a pipeline of potential first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the second qu

      8/14/24 6:05:00 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

      AUSTIN, Texas, July 30, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024 at 4:00 p.m. EDT in Boston, MA. A live webcast of the event can be accessed at https://investors.aileronrx.com/events-presentations/in

      7/30/24 8:00:00 AM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aileron Therapeutics to be Included in the Russell Microcap® Index

      AUSTIN, Texas, July 1, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S.

      7/1/24 8:00:00 AM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

      Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated Topline results from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) expected in the third quarter of 2024 AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the first quarter ended March 31, 2024, and provided a busine

      5/15/24 5:13:03 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Aileron Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Windsor James Brian bought $898 worth of shares (400 units at $2.24) (SEC Form 4)

      4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)

      12/9/24 4:09:30 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Windsor James Brian bought $758 worth of shares (225 units at $3.37) (SEC Form 4)

      4 - AILERON THERAPEUTICS INC (0001420565) (Issuer)

      12/18/23 5:56:31 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Windsor James Brian bought $9,987 worth of shares (5,076 units at $1.97), increasing direct ownership by 11,035% to 5,122 units (SEC Form 4)

      4 - AILERON THERAPEUTICS INC (0001420565) (Issuer)

      11/21/23 4:43:12 PM ET
      $ALRN
      Biotechnology: Pharmaceutical Preparations
      Health Care